EMA Recommends Granting a Marketing Authorisation for Generic Trabectedin By Ogkologos - April 30, 2025 342 0 Facebook Twitter Google+ Pinterest WhatsApp Trabectedin Accord is a generic of Yondelis, which has been authorised in the EU since 2007 Source RELATED ARTICLESMORE FROM AUTHOR AI-Supported Mammography Screening Shows Favourable Outcomes Compared with Standard Double Reading ESMO Welcomes European Parliament Resolution Marking World Cancer Day FDA Approves Daratumumab and Hyaluronidase-fihj with Bortezomib, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma MOST POPULAR Metastatic Breast Cancer: New ESMO Guideline With Evidence-Based Recommendations [ESMO Press... October 19, 2021 Emma Stone Motivated to Help Others After Her Mother Was Diagnosed... November 16, 2020 Dual Inhibition of LAG-3 and PD-1 in Patients with Previously Untreated... January 10, 2022 BREAKING: President Trump May Restore The WHO’s Funding, With Some Conditions May 18, 2020 Load more HOT NEWS Immune cell count could determine whether chemotherapy is required in oropharyngeal... More Than One in 10 Patients With Lung Cancer Do Not... Coping With Life After a Bone Marrow Transplant: A Survivor’s Story A Chemotherapy-Free Regimen of Tucatinib and Trastuzumab Shows Antitumour Activity with...
